The role of UBR4 E3 activity in promoting various diseases such as cancer and muscular atrophy would imply that modulation of UBR4 hemiRING E3 activity might have therapeutic value (for example, by disruption of the UBE2A–hemiRING interface). Here, UBE2A is linked to muscular atrophy.